Search

Your search keyword '"Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF)"' showing total 2 results
Start Over Descriptor "Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF)" Topic atrial fibrillation
2 results on '"Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF)"'

1. Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA 2 DS 2 -VASc Scores: Findings From the ORBIT-AF I and II Registries.

Author

Jackson LR 2nd, Kim S, Fonarow GC, Freeman JV, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Singer D, Thomas L, Blanco R, Peterson ED, and Piccini JP Sr

Subjects
Aged, Aged, 80 and over, Atrial Fibrillation complications, Case-Control Studies, Female, Humans, Ischemic Attack, Transient epidemiology, Ischemic Attack, Transient etiology, Male, Middle Aged, Mortality, Registries, Risk Assessment, Sex Factors, Stroke epidemiology, Stroke etiology, Anticoagulants therapeutic use, Atrial Fibrillation drug therapy, Ischemic Attack, Transient prevention & control, Platelet Aggregation Inhibitors therapeutic use, Stroke prevention & control
Abstract

Background Current American College of Cardiology/American Heart Association guidelines suggest that for patients with atrial fibrillation who are at low risk for stroke (CHA 2 DS 2 VASc=1) (or women with CHA 2 DS 2 VASc=2) a variety of treatment strategies may be considered. However, in clinical practice, patterns of treatment in these "low-risk" patients are not well described. The objective of this analysis is to define thromboembolic event rates and to describe treatment patterns in patients with low-risk CHA 2 DS 2 VASc scores. Methods and Results We compared characteristics, treatment strategies, and outcomes among patients with a CHA 2 DS 2 VASc=0, CHA 2 DS 2 VASc=1, females with a CHA 2 DS 2 VASc=2, and CHA 2 DS 2 VASc ≥2 in ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) I & II. Compared with CHA 2 DS 2 VASc ≥2 patients (84.2%), those with a CHA 2 DS 2 VASc=0 (60.3%), 1 (69.9%), and females with a CHA 2 DS 2 VASc score=2 (72.4%) were significantly less often treated with oral anticoagulation ( P<0.0001). Stroke rates were low overall and ranged from 0 per 100 patient-years in those with CHA 2 DS 2 VASc=0, 0.8 (95% confidence interval [CI] [0.5-1.2]) in those with CHA 2 DS 2 VASc=1, 0.8 (95% CI [0.4-1.6]) in females with a CHA 2 DS 2 VASc score=2, and 1.7 (95% CI [1.6-1.9]) in CHA 2 DS 2 VASc ≥2. All-cause mortality (per 100 patient-years) was highest in females with a CHA 2 DS 2 VASc score=2 (1.4) (95% CI [0.8-2.3]), compared with patients with a CHA 2 DS 2 VASc=0 (0.2) (95% CI [0.1-1.0]), and CHA 2 DS 2 VASc=1 (1.0) (95% CI [0.7-1.4]), but lower than patients with a CHA 2 DS 2 VASc ≥2 (5.7) (95% CI [5.4-6.0]). Conclusion The majority of CHA 2 DS 2 VASc=0-1 patients are treated with oral anticoagulation. In addition, the absolute risks of death and stroke/transient ischemic attack were low among both male and females CHA 2 DS 2 VASc=0-1 as well as among females with a CHA 2 DS 2 VASc score=2. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique identifier: NCT01701817.

Published
2018
Full Text
View/download PDF

2. Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA 2 DS 2 ‐VASc Scores: Findings From the ORBIT‐AF I and II Registries

Author

Bernard J. Gersh, Gregg C. Fonarow, James V. Freeman, Peter R. Kowey, Eric D. Peterson, Alan S. Go, Laine Thomas, Sunghee Kim, Jonathan P. Piccini, Rosalia Blanco, Kenneth W. Mahaffey, Elaine M. Hylek, Daniel E. Singer, Investigators, and Larry R. Jackson

Subjects
Male, medicine.medical_specialty, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF), 030204 cardiovascular system & hematology, Risk Assessment, Stroke risk, 03 medical and health sciences, Sex Factors, 0302 clinical medicine, Internal medicine, Atrial Fibrillation, medicine, Humans, Arrhythmia and Electrophysiology, In patient, Registries, 030212 general & internal medicine, Mortality, Stroke, Oral anticoagulation, Original Research, Aged, oral anticoagulation, Aged, 80 and over, Quality and Outcomes, business.industry, Anticoagulants, Atrial fibrillation, Middle Aged, medicine.disease, stroke, Confidence interval, Clinical Practice, Clinical trial, Ischemic Attack, Transient, Case-Control Studies, Female, Cardiology and Cardiovascular Medicine, business, Platelet Aggregation Inhibitors
Abstract

Background Current American College of Cardiology/American Heart Association guidelines suggest that for patients with atrial fibrillation who are at low risk for stroke (CHA 2 DS 2 VASc=1) (or women with CHA 2 DS 2 VASc=2) a variety of treatment strategies may be considered. However, in clinical practice, patterns of treatment in these “low‐risk” patients are not well described. The objective of this analysis is to define thromboembolic event rates and to describe treatment patterns in patients with low‐risk CHA 2 DS 2 VASc scores. Methods and Results We compared characteristics, treatment strategies, and outcomes among patients with a CHA 2 DS 2 VASc=0, CHA 2 DS 2 VASc=1, females with a CHA 2 DS 2 VASc=2, and CHA 2 DS 2 VASc ≥2 in ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) I & II. Compared with CHA 2 DS 2 VASc ≥2 patients (84.2%), those with a CHA 2 DS 2 VASc=0 (60.3%), 1 (69.9%), and females with a CHA 2 DS 2 VASc score=2 (72.4%) were significantly less often treated with oral anticoagulation ( P 2 DS 2 VASc=0, 0.8 (95% confidence interval [CI] [0.5–1.2]) in those with CHA 2 DS 2 VASc=1, 0.8 (95% CI [0.4–1.6]) in females with a CHA 2 DS 2 VASc score=2, and 1.7 (95% CI [1.6–1.9]) in CHA 2 DS 2 VASc ≥2. All‐cause mortality (per 100 patient‐years) was highest in females with a CHA 2 DS 2 VASc score=2 (1.4) (95% CI [0.8–2.3]), compared with patients with a CHA 2 DS 2 VASc=0 (0.2) (95% CI [0.1–1.0]), and CHA 2 DS 2 VASc=1 (1.0) (95% CI [0.7–1.4]), but lower than patients with a CHA 2 DS 2 VASc ≥2 (5.7) (95% CI [5.4–6.0]). Conclusion The majority of CHA 2 DS 2 VASc=0‐1 patients are treated with oral anticoagulation. In addition, the absolute risks of death and stroke/transient ischemic attack were low among both male and females CHA 2 DS 2 VASc=0‐1 as well as among females with a CHA 2 DS 2 VASc score=2. Clinical Trial Registration URL: http://www.clinicaltrials.gov . Unique identifier: NCT01701817.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results